inno.N

- Expansion follows an exclusive License and Supply Agreement signed in 2024 with Tabuk Pharmaceuticals for K-CAB in ten countries in the Middle East and North Africa

- K-CAB has now entered 54 countries worldwide and is continuing its global expansion

K-CAB, HK inno.N’s new drug for gastroesophageal reflux disease (GERD), is expanding its presence in the global market.

HK inno.N announced on the 7th (MAY 7) that the company recently expanded its collaboration with Tabuk Pharmaceuticals  for K-CAB tablets (active ingredient tegoprazan), its new GERD treatment, to include additional six countries in the MENA region.

HK inno.N  signed an Agreement with Tabuk Pharmaceuticals in 2024 to for the exclusive License and Supply rights in 10 countries in the Middle East and North Africa. The new agreement with Tabuk Pharmaceuticals will expand the territory to include 6 new MENA countries; Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya.

In addition to exporting technology, K-CAB is expanding its global presence through the export of finished products. Including this agreement, the company has reached a total of 53 overseas countries, excluding Korea.

Tabuk Pharmaceuticals is a leading Saudi pharmaceutical company with a regional presence in the Middle East and North Africa with strong distribution and marketing capabilities across the Middle East and North Africa and is expected to play an important role in the market penetration and expansion of K-CAB in the MENA region.

Kwak Dal-won, CEO of HK inno.N, said, “With this agreement, we have reached 53 countries, more than halfway to our goal of reaching 100 countries by 2028. We will continue to work closely with our partners in each country to establish K-CAB as a paradigm-shifting new drug for the treatment of GERD worldwide.” Ismail Shehada, CEO of Tabuk, said “We consider our partnership with HK inno.N to be a strategic pillar of our growth. We are pleased to expand our collaboration not only by extending our presence into additional countries, but also by broadening our portfolio with new products in the future. This reinforces our shared commitment to improving patient access and delivering innovative healthcare solutions globally. ”

K-CAB, the 30th new drug in South Korea, is a P-CAB class new drug for GERD treatment and is addressing the market with various formulations (IR tablets, oral disintegrating tablets) and indications (5 in total). It is characterized by rapid onset of action within one hour after administration and proven efficacy and safety even with long-term use for up to six months. 

Following its first launch in South Korea, K-CAB succeeded in the market entry to a total of 54 countries worldwide and has been officially released in 15 countries to date. K-CAB recorded total outpatient prescription sales of KRW 196.9 billion in 2024 in South Korea. The product has been the steady No. 1 market leader in peptic ulcer medications for five consecutive years. [The End]

[Reference information]

■ P-CAB: Potassium Competitive Acid Blocker

■ Overview of K-CAB’s market presence worldwide (54 countries in total): 

- South Korea, China, Mongolia, India, South Africa, the United States, Canada, Australia, New Zealand

- 6 Southeast Asian countries: Indonesia, Thailand, Philippines, Vietnam, Singapore, Malaysia

- 5 Eastern European countries: Russia, Kazakhstan, Uzbekistan, Ukraine, Belarus

- 18 Central and South American countries: Brazil, Mexico, Argentina, Colombia, Peru, Chile, Ecuador, Uruguay, Paraguay, Bolivia, Venezuela, Dominican Republic, Guatemala, Honduras, Nicaragua, Costa Rica, Panama, El Salvador

- 16 Middle Eastern/North African countries: Saudi Arabia, Jordan, Lebanon, UAE, Oman, Kuwait, Bahrain, Iraq, Qatar, Algeria, Egypt, Sudan, Ethiopia, Morocco, Yemen, Libya